Adial Pharmaceuticals

Yahoo Finance • 2 months ago

Adial Pharmaceuticals reports Q2 results

* Adial Pharmaceuticals press release [https://seekingalpha.com/pr/20201045-adial-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:ADIL [https://seekingalpha.com/symbol/ADIL]): Q2 net Loss was $... Full story

Yahoo Finance • 2 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 2 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock... Full story

Yahoo Finance • 2 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] AFTER HOURS GAINERS TICKER CHANGE... Full story

Yahoo Finance • 2 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 3 months ago

Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL).Thermo Fisher Scientific (TMO) In... Full story

Yahoo Finance • 3 months ago

Adial Pharmaceuticals files patent update for alcohol disorder treatment

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a micro-cap pharmaceutical company with a market capitalization of $5 million, announced on Wednesday it has filed an update to its provisional patent application for AD04, the c... Full story

Yahoo Finance • 3 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 3 months ago

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

Company Logo The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health technologies. Advancements in pharmacoth... Full story

Yahoo Finance • 3 months ago

Adial signs manufacturing deals for alcohol disorder drug trials

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a micro-cap pharmaceutical company with a market capitalization of $3.62 million, has secured manufacturing agreements with Thermo Fisher Scientific and Cambrex to produce its in... Full story

Yahoo Finance • 3 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Vali... Full story

Yahoo Finance • 3 months ago

Adial Pharmaceuticals announces pricing of $3.6M public offering

* Adial Pharmaceuticals (NASDAQ:ADIL [https://seekingalpha.com/symbol/ADIL]) on Tuesday announced the pricing of its public offering for the purchase and sale of 11.1M shares of common stock of the company, together with Series D warrant... Full story

Yahoo Finance • 4 months ago

Adial Pharmaceuticals files to register resale of 6.7M shares from warrant conversions

* Adial Pharmaceuticals (NASDAQ:ADIL [https://seekingalpha.com/symbol/ADIL]) is registering up to 6.73M shares of common stock for resale by certain selling stockholders. * The shares include over 6.5M issuable from Series B-1 and C-1... Full story

Yahoo Finance • 5 months ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addic... Full story

Yahoo Finance • 5 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 7 months ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval Adial moves forward with manufacturing of clin... Full story

Yahoo Finance • 7 months ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders Patent expands the identification of potential treatment candidates for AD04 administration based on the p... Full story

Yahoo Finance • 8 months ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 8 months ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions Adial’s formulation exhibited predictable bioavailability relative to... Full story

Yahoo Finance • 2 years ago

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

CHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of... Full story